[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100631306":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":25,"locations":34,"responsibleParty":61,"collaborators":64,"id":81,"slug":25,"hasResults":82,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":82,"sex":88,"minAge":89,"maxAge":25,"enrollmentInfo":90,"targetDuration":25,"studyType":93,"phases":94,"briefSummary":96,"conditions":97,"keywords":103,"overallStatus":36,"whyStopped":25,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":116},{"fullName":5,"class":6},"Sahlgrenska University Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Surgery group","ACTIVE_COMPARATOR","Undergoing primary RPLND",[13],"Procedure: primary RPLND for low-stage metasatatic seminoma",{"label":15,"type":10,"description":16,"interventionNames":17},"Chemotherapy group","Receiving chemotherapy",[18],"Drug: 3 courses of chemotherapy; Blemocin, Etoposide and Platinum (BEP)",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"PROCEDURE","primary RPLND for low-stage metasatatic seminoma","surgical lymph node dissection",[9],null,{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"DRUG","3 courses of chemotherapy; Blemocin, Etoposide and Platinum (BEP)","systemic tretament for good prognosis metastastic testicular cancer",[15],[32,33],"Systemic chemotherapy","Bleomycin, Etoposide, Platinum",[35],{"facility":5,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"RECRUITING","Gothenburg","Göteborg","413 45","Sweden","SE",{"type":43,"coordinates":44},"Point",[45,46],11.96679,57.70716,{"lat":46,"lon":45},[49,54,58],{"name":50,"role":51,"phone":52,"phoneExt":25,"email":53},"Anna LA Grenabo Bergdahl, ass prof","CONTACT","0046 31 342 90 26","anna.grenabo@vgregion.se",{"name":55,"role":51,"phone":56,"phoneExt":25,"email":57},"Hege Haugnes, Prof","004777754342","Hege.Sagstuen.Haugnes@unn.no",{"name":59,"role":60,"phone":25,"phoneExt":25,"email":25},"Hege Haugnes, professor","PRINCIPAL_INVESTIGATOR",{"type":60,"investigatorFullName":62,"investigatorTitle":63,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Anna Grenabo Bergdahl","Urologist, Associate Professor",[65,67,69,71,73,75,77,79],{"name":66,"class":6},"Karolinska University Hospital",{"name":68,"class":6},"Haukeland University Hospital",{"name":70,"class":6},"University Hospital of North Norway",{"name":72,"class":6},"Oslo University Hospital",{"name":74,"class":6},"Trondheim University Hospital",{"name":76,"class":6},"Uppsala University Hospital",{"name":78,"class":6},"University Hospital, Umeå",{"name":80,"class":6},"Lund University Hospital","100631306",false,"NCT07498959","Primary RPLND Versus Systemic Chemotherapy in Good-prognosis Metastatic Testicular Cancer","Testicular Cancer Treatment: Assessing Quality of Life in Good Prognosis Metastastic Disease","TESTIGO","Inclusion Criteria:\n\n* Patients ≥18 years undergoing an open or minimally invasive primary retroperitoneal lymph node dissection (RPLND) due to seminoma stage II A\u002FB (maximum 2 nodes, \\\u003C30 mm in any dimension)\n* Patients undergoing an open or minimally invasive primary RPLND due to a retroperitoneal relapse of seminoma (maximum 2 nodes, \\\u003C30 mm in any dimension)\n* Patients ≥18 years scheduled for 3-4 courses of chemotherapy due to a newly diagnosed good-prognosis metastatic germ cell tumor (nonseminoma or seminoma)\n\nExclusion Criteria:\n\n* Previous chemotherapy (including adjuvant chemotherapy at diagnosis)\n* Previous RPLND\n* Practical considerations, such as not being able to read and sign informed consent or understand the questionnaires","MALE","18 Years",{"count":91,"type":92},160,"ESTIMATED","INTERVENTIONAL",[95],"NA","The goal of this prospective observational study is to learn about the short- and long-term effects of treating men over the age of 18 with good prognosis metastatic testicular cancer with either primary retropertioneal lymph node dissection, RPLND, (for low-stage metastastic seminoma) or three doses of chemotherapy for metastastic seminoma or nonseminoma. The main question it aims to answer is:\n\nDoes primary RPLND lower the risk of side-effects compared to receiving chemotherapy?",[98,99,100,101,102],"Testicular Cancer","Seminoma","Quality of Life","De-escalation","RPLND",[104,105,106],"testicular cancer","seminoma","primary RPLND","2026-03-24",{"date":109,"type":110},"2026-03-27","ACTUAL",{"date":112,"type":110},"2026-03-19",{"date":114,"type":92},"2032-03-25",{"name":5,"class":6},1]